AKERO THERAPEUTICS

Akero Therapeutics is committed to providing meaningful treatment options for people with serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by inflammation in the liver and liver cell damage resulting in fibrosis, cirrhosis, liver failure, and death. The company is developing pioneering medicines designed to restore metabolic balance and halt NASH progression. Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 protein and potential best-in-class treatment for NASH. The AKR-001 builds upon two decades of work on FGF21 biology. It is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.

#SimilarOrganizations #People #Financial #Website #More

AKERO THERAPEUTICS

Social Links:

Industry:

Biotechnology Life Science Therapeutics

Founded:

2017-01-01

Address:

Cambridge, Massachusetts, United States

Country:

United States

Website Url:

http://www.akerotx.com

Total Employee:

11+

Status:

Active

Email Addresses:

[email protected]

Total Funding:

260 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress